フリードライヒ運動失調症の市場規模・シェア・展望・機会 (2022年～2030年)：薬剤クラス (ACE阻害剤・ベータ遮断剤・利尿剤・パラベンゾキノン・その他)・投与経路・流通経路・地域別

フリードライヒ運動失調症の高い医療負担、技術的進歩、主要企業によるM&Aや提携などの無機的成長戦略の採用などの要因が予測期間中の世界のフリードライヒ運動失調症市場の成長を促進すると予測されています。

当レポートでは、世界のフリードライヒ運動失調症の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制・償還環境、パイプラインの分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学・規制・動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
• 影響分析
• パイプライン分析
• PEST分析
• 規制シナリオ
• 市場動向
• 主なハイライト
• 償還シナリオ
• M&A

第4章 世界のフリードライヒ運動失調症市場：COVID-19の影響

• COVID-19：疫学
• 需要・サプライチェーンの分析

第5章 世界のフリードライヒ運動失調症市場：薬剤クラス別

• ACE阻害剤
• ベータ遮断薬
• 利尿薬
• パラベンゾキノン
• その他（ビタミンE、免疫調節薬、骨格筋弛緩薬、抗てんかん薬など）

第6章 世界のフリードライヒ運動失調症市場：投与経路別

• 経口
• 注射

第7章 世界のフリードライヒ運動失調症市場：流通経路別

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界のフリードライヒ運動失調症市場：地域別

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• ヒートマップ分析
• 市場シェア分析
  • Reata Pharmaceuticals, Inc.
  • Retrotope Inc.
  • Minoryx
  • PTC Therapeutics
  • Design Therapeutics, Inc.
  • Larimar Therapeutics, Inc.
  • Jupiter Neurosciences, Inc.
  • Lexeo Therapeutics
  • Zydus Lifesciences Ltd.
  • Cipla Limited
  • GlaxoSmithKline Plc.
  • Aurobindo Pharma Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd.
• アナリストの見解

第10章 セクション

Ataxia refers to a group of degenerative neurological diseases that affect coordination and movement center of the brain (cerebellum). People suffering from ataxia have difficulty in swallowing, speech, and maintaining balance or coordination. Ataxia can be of several types such as spinocerebellar ataxia, Friedreich's ataxia, ataxia-telangiectasia, multiple system atrophy (MSA), episodic ataxia, and others. Friedreich's ataxia can develop at any age and is progressive in nature i.e. it worsens with time. Friedreich's ataxia (FA) is a genetic ataxia that is caused when a damaged gene which leads to FA is passed from one generation to the other. In addition to common movement related symptoms, people suffering from Friedreich's ataxia also experience symptoms such as stiffness and loss of sensation in muscles, weakness in the body, heart condition (hypertrophic cardiomyopathy), and others.

Market Dynamics

High burden of Friedreich's ataxia, rising technological advancements, and increasing adoption of inorganic growth strategies such as acquisitions, mergers, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global Friedreich's ataxia market over the forecast period.

For instance, according to a review article published by the Frontiers in Neuroscience journal, a peer-reviewed open access scientific journal, in February 2022, it was estimated that the prevalence of Friedreich ataxia was 1:50,000 individuals, around the globe as of 2021

Moreover, in February 2019, the University of Oxford, England and Harrington Discovery Institute at University Hospitals in Ohio, U.S. announced a global partnership to address unmet need of patients suffering from rare diseases such as muscular dystrophy, cystic fibrosis, ataxia, and others

Key features of the study:

• This report provides an in-depth analysis of the global Friedreich's ataxia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new Material launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Friedreich's ataxia market based on the following parameters - company overview, financial performance, Material portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Reata Pharmaceuticals, Inc., Retrotope Inc., Minoryx, PTC Therapeutics, Design Therapeutics, Inc., Larimar Therapeutics, Inc., Jupiter Neurosciences, Inc., Lexeo Therapeutics, Zydus Lifesciences Ltd., Cipla Limited, GlaxoSmithKline Plc., Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Intas Pharmaceuticals Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future Material launches, type up-gradation, market expansion, and marketing tactics
• The global Friedreich's ataxia market report caters to various stakeholders in this industry including investors, suppliers, Material manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Friedreich's ataxia market

Detailed Segmentation:

• Global Friedreich's Ataxia Market, By Drug Class:
  • ACE Inhibitors
  • Beta Blockers
  • Diuretics
  • Para-Benzoquinone
  • Others (Vitamin E, immunomodulators, skeletal muscle relaxants, and anti-epileptic drugs, among others)
• Global Friedreich's Ataxia Market, By Route of Administration:
  • Oral
  • Injectable
• Global Friedreich's Ataxia Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Friedreich's Ataxia Market, By Region:
  • North America
    • By Country
    • U.S.
    • Canada
  • Latin America
    • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By Country
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By Country/Region
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Reata Pharmaceuticals, Inc.*
    • Company Overview
    • Material Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • Retrotope Inc.
  • Minoryx
  • PTC Therapeutics
  • Design Therapeutics, Inc.
  • Larimar Therapeutics, Inc.
  • Jupiter Neurosciences, Inc.
  • Lexeo Therapeutics
  • Zydus Lifesciences Ltd.
  • Cipla Limited
  • GlaxoSmithKline Plc.
  • Aurobindo Pharma Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Pipeline Analysis
• PEST Analysis
• Regulatory Scenario
• Market Trends
• Key Highlights
• Reimbursement Scenario
• Mergers & Acquisitions

4. Global Friedreich's Ataxia Market - Impact of Coronavirus (Covid-19) Pandemic

• COVID 19 Epidemiology
• Demand and Supply Chain Analysis

5. Global Friedreich's Ataxia Market, By Drug Class, 2017 - 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• ACE Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
• Beta Blockers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
• Diuretics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
• Para-Benzoquinone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
• Others (Vitamin E, Immunomodulators, Skeletal Muscle Relaxants, and Anti-Epileptic Drugs, among others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

6. Global Friedreich's Ataxia Market, By Route of Administration, 2017 - 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

7. Global Friedreich's Ataxia Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

8. Global Friedreich's Ataxia Market, By Region, 2017 - 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2018-2030
• North America
  • Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • U.S.
  • Canada
• Latin America
  • Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
  • Market Size and Forecast, By Country/Region, 2017 - 2030, (US$ Mn)
  • South Africa
  • Central Africa
  • North Africa

9. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
  • Reata Pharmaceuticals, Inc.
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Retrotope Inc.
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Minoryx
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • PTC Therapeutics
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Design Therapeutics, Inc.
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Larimar Therapeutics, Inc.
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Jupiter Neurosciences, Inc.
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Lexeo Therapeutics
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Zydus Lifesciences Ltd.
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Cipla Limited
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • GlaxoSmithKline Plc.
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Aurobindo Pharma Ltd.
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Torrent Pharmaceuticals Ltd.
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Intas Pharmaceuticals Ltd.
  • Company Overview
  • Material Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
• Analyst Views

10. Section

• References
• Research Methodology
• About us and Sales Contact